Panic Disorder Market: Growth, Trends, and Future Outlook (2025-2034)

Market Overview

Panic disorder is a severe anxiety condition characterized by recurring panic attacks, which can be unpredictable and debilitating. A panic attack typically involves sudden feelings of intense fear or discomfort, often accompanied by physical symptoms such as heart palpitations, sweating, and shortness of breath. In recent years, there has been a growing emphasis on improving mental health, which has led to increased awareness and diagnosis of mental health disorders like panic disorder. This has consequently driven the demand for effective treatment options, including medications and therapies.

The panic disorder market, valued at USD 9.7 billion in 2024 across the 7 major markets (United States, EU-4, UK, Japan), is projected to grow at a compound annual growth rate (CAGR) of 4.18%. By 2034, the market is expected to reach a value of approximately USD 14 billion. This growth is attributed to various factors, including greater awareness, improved treatment modalities, the availability of novel drugs, and the growing focus on mental health care across the globe.

Market Size and Share

The panic disorder market in the 7 major markets was valued at USD 9.7 billion in 2024. This figure reflects a significant demand for treatment options as mental health issues, including anxiety disorders, gain more recognition. With an expected growth rate of 4.18% CAGR during the forecast period (2025-2034), the market is projected to grow from USD 10.1 billion in 2025 to USD 14 billion by 2034. This upward trajectory is driven by increasing incidences of panic disorder, a more extensive understanding of the condition, and the rising adoption of both pharmacological and non-pharmacological treatments.

North America holds the largest market share, driven by the increased focus on mental health in the region and the availability of effective treatments. Europe and Japan also contribute significantly, with growing healthcare investments and rising awareness of panic disorder. Market players are increasingly focusing on developing new therapies and expanding access to treatment options to tap into these growing markets.

Get a free sample request: https://www.expertmarketresearch.com/reports/panic-disorder-market/requestsample

Market Trends

Increased Focus on Mental Health Awareness
The growing emphasis on mental health awareness is helping reduce the stigma associated with anxiety disorders and panic attacks. As a result, more people are seeking help, and healthcare providers are diagnosing and treating panic disorder earlier. This trend is expanding the demand for both medications and therapeutic interventions, driving market growth.
Growth in Online Therapy and Telemedicine
The rise of telemedicine and online therapy platforms is revolutionizing mental health care, making treatment more accessible and convenient for patients with panic disorder. Teletherapy options such as cognitive-behavioral therapy (CBT) have become more popular, especially during the COVID-19 pandemic, and are expected to continue growing in the coming years.
Introduction of New Drug Formulations
The panic disorder market is witnessing the introduction of innovative drug formulations, particularly those targeting serotonin and norepinephrine reuptake inhibitors (SNRIs). These drugs, along with other anxiolytics and antidepressants, are expected to enhance patient outcomes and provide effective treatment options with fewer side effects.
Rise in Co-morbidities
Panic disorder often co-occurs with other conditions such as generalized anxiety disorder (GAD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). This association is increasing the demand for combined treatments that can address multiple mental health conditions simultaneously, thus broadening the scope of the panic disorder treatment market.

Market Analysis

Increasing Diagnosis and Awareness
As more people are diagnosed with panic disorder and related anxiety conditions, the market for treatments continues to expand. Governments, non-profit organizations, and healthcare institutions are working together to raise awareness about panic disorder, resulting in more individuals seeking professional help. The growing trend of mental health advocacy is fueling market growth.
Adoption of Cognitive Behavioral Therapy (CBT)
Cognitive-behavioral therapy (CBT) is considered one of the most effective treatments for panic disorder. Its widespread adoption, especially with the increasing availability of online CBT services, is boosting market demand. CBT offers long-term benefits by teaching individuals how to manage their anxiety and panic attacks, leading to improved outcomes for patients.
Use of Anxiolytics and Antidepressants
The use of anxiolytics, including benzodiazepines, and antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) remains the primary pharmacological treatment for panic disorder. These drug classes are integral to market growth, with continuous advancements in formulations and reduced side-effect profiles.
Increased Support for Mental Health Research
Research into novel treatments for mental health conditions, including panic disorder, is receiving increased funding from both government and private sectors. This is expected to result in new drug discoveries and improved treatment modalities, further expanding the panic disorder market. Clinical trials focusing on innovative pharmacotherapies and non-pharmacological treatments are likely to be key growth drivers.

Market Segmentation

Scope of the Report

This report examines the historical and forecast market trends, key industry drivers, constraints, and market analysis by various segments, including type, therapy, drug class, route of administration, and region. It provides a comprehensive overview of the panic disorder treatment landscape across different market segments and regions.

Breakup by Type

Agoraphobia
Agoraphobia, the fear of being in situations where escape might be difficult, is often associated with panic disorder. The growing recognition of agoraphobia as a symptom of panic disorder is expected to drive demand for treatments, especially for patients suffering from panic attacks triggered by public spaces or crowds.
Social Anxiety Disorder (SAD)
Social anxiety disorder, characterized by overwhelming fear of social situations, is closely related to panic disorder. As these disorders often co-occur, the demand for treatments that address both conditions is growing. The market for SAD and panic disorder treatments is expanding due to overlapping patient populations.
Obsessive-Compulsive Disorder (OCD)
OCD, which involves intrusive thoughts and compulsive behaviors, is frequently co-diagnosed with panic disorder. This has led to a demand for combined therapies that target both OCD and panic disorder, contributing to the growth of the panic disorder market.
Other Types
Other types of anxiety and mood disorders, including generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and major depressive disorder (MDD), often share symptoms with panic disorder. This overlap has spurred the development of multi-target treatments, driving market expansion.

Breakup by Therapy

Electroconvulsive Therapy (ECT)
ECT is primarily used in severe cases of panic disorder and depression when other treatments fail. Although less commonly used than pharmacological treatments, ECT remains a critical option for patients with treatment-resistant panic disorder. As research into brain stimulation therapies continues, ECT may play a larger role in future treatment paradigms.
Cognitive-Behavioral Therapy (CBT)
CBT is considered the gold standard for treating panic disorder and is widely used across both inpatient and outpatient settings. With the rise of online CBT platforms, the accessibility and effectiveness of this treatment have increased. The broad adoption of CBT for panic disorder treatment will continue to be a key driver of market growth.

Breakup by Drug Class

Benzodiazepines (BZD)
Benzodiazepines, such as alprazolam and lorazepam, are frequently prescribed to manage the acute symptoms of panic disorder. While effective in the short term, concerns over dependence and side effects have driven research into safer alternatives.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
SNRIs, such as venlafaxine, are widely used to treat both panic disorder and generalized anxiety disorder. Their dual action on serotonin and norepinephrine helps manage panic attacks more effectively than selective serotonin reuptake inhibitors (SSRIs), driving their increasing use in the panic disorder market.
Other Drug Classes
Other drug classes, including monoamine oxidase inhibitors (MAOIs), anti-depressants, and pregabalin, are also utilized for panic disorder treatment. Research into new formulations and combinations of these drugs is ongoing, which may further enhance treatment efficacy and market growth.

Breakup by Route of Administration

Oral
Oral medications, including benzodiazepines and antidepressants, remain the most common route of administration for panic disorder. Oral drugs are preferred due to their convenience, ease of use, and ability to be taken at home, thus driving their dominance in the market.
Parenteral
Parenteral administration, such as injections, is less common for panic disorder treatment. However, it is used in acute cases, particularly for patients who may not be able to take oral medications or who require rapid relief from symptoms.

Regional Insights

United States

The United States holds the largest share of the panic disorder market, driven by a robust healthcare infrastructure and high levels of awareness regarding mental health. The U.S. also leads in terms of research and development, with numerous pharmaceutical companies focused on advancing treatments for anxiety disorders. Increased government funding for mental health initiatives is expected to further boost market growth.

copyright

copyright also has a significant market share, with increasing recognition of mental health issues and a growing demand for therapy and pharmacological treatments. copyright’s healthcare system prioritizes mental health care, and government support for mental health services is helping drive the adoption of panic disorder treatments across the country.

Market Growth

Factors driving growth in the panic disorder market include the increasing prevalence of anxiety disorders, the rise in mental health awareness, and the availability of both pharmacological and non-pharmacological treatments. New drug formulations, alongside the expansion of online therapy services, are expected to drive market expansion. Research into combined therapies and treatment-resistant panic disorder will offer additional growth opportunities.

Recent Developments & Challenges

Telemedicine for Mental Health
The rapid growth of telemedicine services has made panic disorder treatment more accessible, especially during the COVID-19 pandemic. The convenience of online therapy has increased the adoption of cognitive-behavioral therapy (CBT) and other therapeutic interventions.
New Drug Formulations
Research and development in the field of psychopharmacology have led to the introduction of new drug formulations for panic disorder. These drugs aim to provide better efficacy with fewer side effects, thus improving patient outcomes and satisfaction.
Regulatory Support for Mental Health
Government initiatives aimed at supporting mental health care have led to increased funding for research and expanded access to treatments. These initiatives are crucial for the growth of the panic disorder market, ensuring that patients have access to the latest therapies.
Challenges in Treatment Accessibility
Despite growing awareness, some regions still face challenges in providing access to effective treatments for panic disorder. Economic barriers, healthcare infrastructure limitations, and stigma can hinder patients from seeking timely care.

Key Players

Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical is a major player in the panic disorder market, offering various treatment options, including generic drugs for anxiety and panic disorders. Teva’s broad portfolio and global presence make it a key contributor to the market.
AstraZeneca
AstraZeneca has a strong presence in the mental health market, with multiple therapies aimed at treating anxiety and mood disorders. The company’s ongoing research into innovative drug classes supports its position as a market leader.

Bristol-Myers Squibb Company
Bristol-Myers Squibb is heavily invested in the mental health space, with a particular focus on anxiety disorders. The company’s robust pipeline and commitment to advancing panic disorder treatments are contributing to market growth.
GlaxoSmithKline plc
GlaxoSmithKline offers several medications for treating panic disorder and related anxiety conditions. The company’s investment in both research and patient care initiatives positions it as a key player in the growing panic disorder market.

Other companies involved in the market include Sun Pharmaceutical Industries Ltd., Mylan, and Recordati S.p.A.

Blog